All amounts are in U.S. dollars
QUEBEC CITY, Feb. 28 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ: AEZS)
(TSX: AEZ) (the "Company"), a late-stage drug development company
specialized in oncology and endocrinology, today announced that it had
received a net sales milestone of $2.5 million from Cowen Healthcare
Royalty Partners, L.P. ("Cowen Royalty"). This milestone was payable
pursuant to the previously announced sale to Cowen Royalty of Aeterna
Zentaris' rights to royalties on future net sales of Cetrotide®, covered by the Company's license agreement with Merck Serono, and was
contingent on 2010 net sales of Cetrotide® reaching a specified level.
Juergen Engel, Ph.D., President and CEO of Aeterna Zentaris stated, "We
are pleased to have reached this $2.5 million milestone which will be
incremental to advance perifosine, AEZS-108 and other innovative
oncology compounds from our extensive product pipeline."
Cetrotide® was the first luteinizing hormone-releasing hormone antagonist
treatment approved for in vitro fertilization. It is administered to women to prevent premature
ovulation in order to increase fertility success rate. It was launched
in Europe in 1999 and in the United States in 2001. Cetrotide® is currently marketed worldwide by Merck Serono, except for Japan where
it is marketed by Nippon Kayaku and Shionogi.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a late-stage oncology drug development company
currently investigating potential treatments for various cancers
including colorectal, ovarian, endometrial cancer and multiple myeloma.
The Company's innovative approach of "personalized medicine" means
tailoring treatments to a patient's specific condition and to unmet
medical needs. Aeterna Zentaris' deep pipeline is drawn from its
proprietary discovery unit providing the Company with constant and
long-term access to state-of-the-art therapeutic options. For more
information please visit www.aezsinc.com.
About Cowen Healthcare Royalty Partners
Cowen Healthcare Royalty Partners is a global healthcare investment firm
with more than $1 billion under management. The Firm invests
principally in commercial-stage healthcare companies and products
through drug royalty acquisitions and structured financings. Cowen
Royalty's investment team has over 100 years of healthcare related
experience including principal investing, structured finance,
healthcare industry senior management, Wall Street research and
consulting, and scientific and clinical experience. For more
information, visit www.cowenroyalty.com.
This press release contains forward-looking statements made pursuant to
the safe harbour provisions of the U.S. Securities Litigation Reform
Act of 1995. Forward-looking statements involve known and unknown risks
and uncertainties that could cause the Company's actual results to
differ materially from those in the forward-looking statements. Such
risks and uncertainties include, among others, the availability of
funds and resources to pursue R&D projects, the successful and timely
completion of clinical studies, the ability of the Company to take
advantage of business opportunities in the pharmaceutical industry,
uncertainties related to the regulatory process and general changes in
economic conditions. Investors should consult the Company's quarterly
and annual filings with the Canadian and U.S. securities commissions
for additional information on risks and uncertainties relating to
forward-looking statements. Investors are cautioned not to rely on
these forward-looking statements. The Company does not undertake to
update these forward-looking statements. We disclaim any obligation to
update any such factors or to publicly announce the result of any
revisions to any of the forward-looking statements contained herein to
reflect future results, events or developments, unless required to do
so by a governmental authority or by applicable law.
SOURCE AETERNA ZENTARIS INC.
For further information:
Investor Relations Coordinator
(418) 652-8525 ext. 265
The Investor Relations Group
Director of Communications
(418) 652-8525 ext. 406